Why the study?
Global eradication of poliovirus remains elusive, making the development of next generation vaccines and antivirals critical.
The human monoclonal antibody 9H2 neutralizes all three poliovirus serotypes by outcompeting the poliovirus receptor, making it a potential antiviral candidate.
Answers are grounded in this paper and cite their sources.
May guide pan-serotype poliovirus countermeasures; leaves open clinical translation.
Global eradication of poliovirus remains elusive, and it is critical to develop next generation vaccines and antivirals. In support of this goal, we map the epitope of human monoclonal antibody 9H2 which is able to neutralize the three serotypes of poliovirus. Using cryo-EM we solve the near-atomic structures of 9H2 fragments (Fab) bound to capsids of poliovirus serotypes 1, 2, and 3. The Fab-virus complexes show that Fab interacts with the same binding mode for each serotype and at the same angle of interaction relative to the capsid surface. For each of the Fab-virus complexes, we find that the binding site overlaps with the poliovirus receptor (PVR) binding site and maps across and into a depression in the capsid called the canyon. No conformational changes to the capsid are induced by Fab binding for any complex. Competition binding experiments between 9H2 and PVR reveal that 9H2 impedes receptor binding. Thus, 9H2 outcompetes the receptor to neutralize poliovirus. The ability to neutralize all three serotypes, coupled with the critical importance of the conserved receptor binding site make 9H2 an attractive antiviral candidate for future development.
No takes yet. Share an insight, caveat, or question.
Charnesky et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: